Free Trial

Coloplast A/S (OTCMKTS:CLPBY) Sees Large Decline in Short Interest

Coloplast A/S logo with Medical background

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 62,800 shares, a decrease of 14.3% from the September 30th total of 73,300 shares. Based on an average daily volume of 115,100 shares, the days-to-cover ratio is presently 0.5 days.

Coloplast A/S Stock Up 0.3 %

Shares of CLPBY traded up $0.04 during mid-day trading on Tuesday, hitting $13.07. 57,561 shares of the company's stock were exchanged, compared to its average volume of 131,558. The company has a market cap of $28.23 billion, a PE ratio of 39.61, a P/E/G ratio of 3.30 and a beta of -0.02. Coloplast A/S has a 52 week low of $9.90 and a 52 week high of $14.34. The company has a 50-day simple moving average of $13.33 and a 200 day simple moving average of $12.85. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.85 and a quick ratio of 0.56.

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) last released its quarterly earnings data on Tuesday, August 20th. The company reported $0.08 EPS for the quarter. The company had revenue of $993.49 million during the quarter. Coloplast A/S had a return on equity of 31.39% and a net margin of 18.89%. On average, research analysts forecast that Coloplast A/S will post 0.34 earnings per share for the current fiscal year.

Coloplast A/S Company Profile

(Get Free Report)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.

Further Reading

→ 917 Trades… Zero Losses? (From Insiders Exposed) (Ad)

Should you invest $1,000 in Coloplast A/S right now?

Before you consider Coloplast A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coloplast A/S wasn't on the list.

While Coloplast A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

'Best Report in 2 Years': NVIDIA Earnings Crushes Expectations Again

'Best Report in 2 Years': NVIDIA Earnings Crushes Expectations Again

With revenue growth nearing 95%, margins widening, and earnings soaring 111%, this might be NVIDIA's most impressive performance yet.

Related Videos

How to Profit from NVIDIA’s Earnings: Short-Term Trading Guide
NVIDIA Nears All-Time Highs: How High Can This AI Leader Climb?
What the Bulls and Bears Are Saying About NVIDIA Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines